These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 37114054)

  • 1. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
    Ni J; Si X; Wang H; Zhang X; Zhang L
    Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
    Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
    Liu ZL; Wang B; Liu JZ; Liu WW
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1076-S1083. PubMed ID: 30539849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
    BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab: A Review in Extensive-Stage SCLC.
    Al-Salama ZT
    Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study.
    Lan C; Lu H; Zhou L; Liao K; Liu J; Xie Z; Liang H; Zou G; Yang T; Xu Q; Huang X
    Cancer Commun (Lond); 2024 Jun; 44(6):654-669. PubMed ID: 38741375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Goldman JW; Garassino MC; Chen Y; Özgüroğlu M; Dvorkin M; Trukhin D; Statsenko G; Hotta K; Ji JH; Hochmair MJ; Voitko O; Havel L; Poltoratskiy A; Losonczy G; Reinmuth N; Patel N; Laud PJ; Shire N; Jiang H; Paz-Ares L
    Lung Cancer; 2020 Nov; 149():46-52. PubMed ID: 32961445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
    Fan Y; Zhao J; Wang Q; Huang D; Li X; Chen J; Fang Y; Duan J; Zhou C; Hu Y; Yang H; Hu Y; Zhou J; Lin X; Wang L; Wang Z; Xu Y; Zhang T; Shi W; Zou J; Wang J
    J Thorac Oncol; 2021 Feb; 16(2):299-309. PubMed ID: 33166719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
    Tomono H; Taniguchi H; Fukuda M; Ikeda T; Nagashima S; Akagi K; Ono S; Umeyama Y; Shimada M; Gyotoku H; Takemoto S; Hisamatsu Y; Morinaga R; Tagawa R; Ogata R; Dotsu Y; Senju H; Soda H; Nakatomi K; Hayashi F; Sugasaki N; Kinoshita A; Mukae H
    Thorac Cancer; 2023 Oct; 14(28):2890-2894. PubMed ID: 37675546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
    Chen Y; Chen L; Zhong D
    Thorac Cancer; 2017 May; 8(3):170-180. PubMed ID: 28263036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
    Paz-Ares L; Garassino MC; Chen Y; Reinmuth N; Hotta K; Poltoratskiy A; Trukhin D; Hochmair MJ; Özgüroğlu M; Ji JH; Statsenko G; Conev N; Bondarenko I; Havel L; Losonczy G; Xie M; Lai Z; Godin-Heymann N; Mann H; Jiang H; Shrestha Y; Goldman JW
    Clin Cancer Res; 2024 Feb; 30(4):824-835. PubMed ID: 37801329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
    Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
    Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.